0000899243-22-026421.txt : 20220720 0000899243-22-026421.hdr.sgml : 20220720 20220720180020 ACCESSION NUMBER: 0000899243-22-026421 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220718 FILED AS OF DATE: 20220720 DATE AS OF CHANGE: 20220720 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YVER ANTOINE CENTRAL INDEX KEY: 0001861878 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40445 FILM NUMBER: 221095232 MAIL ADDRESS: STREET 1: C/O CENTESSA PHARMACEUTICALS PLC STREET 2: D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3FH ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Centessa Pharmaceuticals plc CENTRAL INDEX KEY: 0001847903 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3RD FLOOR STREET 2: 1 ASHLEY ROAD CITY: ALTRINCHAM, CHESHIRE STATE: X0 ZIP: WA14 2DT BUSINESS PHONE: 44 7391 789784 MAIL ADDRESS: STREET 1: 3RD FLOOR STREET 2: 1 ASHLEY ROAD CITY: ALTRINCHAM, CHESHIRE STATE: X0 ZIP: WA14 2DT FORMER COMPANY: FORMER CONFORMED NAME: Centessa Pharmaceuticals Ltd DATE OF NAME CHANGE: 20210224 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-18 0 0001847903 Centessa Pharmaceuticals plc CNTA 0001861878 YVER ANTOINE C/O CENTESSA PHARMACEUTICALS PLC 3RD FL., 1 ASHLEY RD, ALTRINCHAM CHESHIRE X0 WA14 2DT UNITED KINGDOM 0 1 0 0 EVP & Chairman of Development Ordinary Shares 2022-07-18 4 S 0 20000 4.8656 D 810597 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 17, 2021, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.74 to $5.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Marella Thorell, attorney-in-fact 2022-07-20